DOCSLIB.ORG

336 Naegeli's

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
336 Naegeli's 336 INDEX N Naegeli's Narrowing - continued - disease 287.1 - artery NEC - continued - leukemia, monocytic (M9863/3) 205.1 -- cerebellar 433.8 Naffziger's syndrome 353.0 -- choroidal 433.8 Naga sore (see also Ulcer, skin) 707.9 -- communicative posterior 433.8 Nagele's pelvis 738.6 -- coronary 414.0 - with disproportion 653.0 --- congenital 090.5 -- causing obstructed labor 660.1 --- due to syphilis 093.8 -- fetus or newborn 763.1 -- hypophyseal 433.8 Nail - see also condition -- pontine 433.8 - biting 307.9 -- precerebral NEC 433.9 - patella syndrome 756.8 --- multiple or bilateral 433.3 Nanism, nanosomia (see also Dwarfism) -- vertebral 433.2 259.4 --- with other precerebral artery 433.3 - pituitary 253.3 --- bilateral 433.3 - renis, renalis 588.0 auditory canal (external) 380.5 Nanukayami 100.8 cerebral arteries 437.0 Napkin rash 691.0 cicatricial - see Cicatrix Narcissism 302.8 eustachian tube 381.6 Narcolepsy 347 eyelid 374.4 Narcosis - intervertebral disc or space NEC - see - carbon dioxide (respiratory) 786.0 Degeneration, intervertebral disc - due to drug - joint space, hip 719.8 -- correct substance properly - larynx 478.7 administered 780.0 mesenteric artery (with gangrene) 557.0 -- overdose or wrong substance given or - palate 524.8 taken 977.9 - palpebral fissure 374.4 --- specified drug - see Table of drugs - retinal artery 362.1 and chemicals - ureter 593.3 Narcotism (chronic) (see also Dependence) - urethra (see also Stricture, urethra) 598.9 304.9 Narrowness, abnormal. eyelid 743.6 - acute NEC Nasal- see condition correct substance properly Nasolachrymal, nasolacrimal- see condition administered 349.8 Nasopharyngeal- see also condition overdose or wrong substance given or - pituitary gland 759.2 taken 965.8 Nasopharyngitis (acute) (infective) --- specified drug - see Table of drugs (subacute) 460 and chemicals - chronic 472.2 Narrow -- due to external agent - see condition, - anterior chamber angle 365.0 respiratory, chronic, due to - pelvis - see Contraction, pelvis - due to external agent - see condition, Narrowing respiratory, due to - artery NEC 447.1 - septic 034.0 -- auditory, internal 433.8 - streptococcal 034.0 -- basilar 433.0 - suppurative (chronic) 472.2 --- with other precerebral artery 433.3 - ulcerative (chronic) 472.2 --- bilateral 433.3 Nasopharynx, nasopharyngeal- see -- carotid 433.1 condition --- with other precerebral artery 433.3 Natal tooth, teeth 520.6 --- bilateral 433.3 Nausea (see also Vomiting) 787.0 DISEASES AND NATURE OF INJURY 337 Nausea - continued Necrosis - continued - epidemic 078.8 - ethmoid (bone) 478.1 - gravidarum 643.0 - eyelid 374.5 - marina 994.6 - fat (generalized) (see also Degeneration, Navel - see condition fatty) 729.3 Nearsightedness 367.1 -- breast (aseptic) 611.3 Nebula, cornea 371.0 -- localized - see Degeneration by site, Necator americanus infestation 126.1 fatty Necatoriasis 126.1 - gallbladder (see also Cholecystitis, acute) Neck - see condition 575.0 Necrencephalus (see also Softening, brain) gastric 537.8 437.8 heart - see Infarct, myocardium Necrobacillosis 040.3 hepatic (see also Necrosis, liver) 570 Necrobiosis 799.8 hip (aseptic) (avascular) 733.4 - brain or cerebral (see also Softening, - intestine (acute) (haemorrhagic) brain) 437.8 (massive) 557.0 - lipoidica 709.3 - jaw 526.4 -- diabeticorum 250.7 t 709.8* - kidney (bilateral) 583.9 Necrolysis, toxic epidermal 695.1 -- acute 584.9 - due to drug -- cortical 583.6 correct substance properly --- acute 584.6 administered 695.1 -- medullary (papillary) (see also Pyelitis) overdose or wrong substance given or 590.8 taken 977.9 --- in --- specified drug - see Table of drugs ---- acute renal failure 584.7 and chemicals ---- nephritis, nephropathy 583.7 Necrophilia 302.8 papillary - see Necrosis kidney, Necrosis, necrotic (ischemic) (see also medullary Gangrene) 785.4 tubular 584.5 - adrenal (capsule) (gland) 255.8 --- with - antrum 478.1 ---- abortion - see categories 634-639, - aorta (hyaline) (see also Aneurysm, fourth digit .3 aorta) 441.6 ---- ectopic or molar pregnancy 639.3 -- cystic medial 441.0 --- complicating pregnancy 648.9 -- ruptured 441.5 ---- fetus or newborn 760.1 - artery 447.5 --- following labor and delivery 669.3 - bladder (aseptic) (sphincter) 596.8 larynx 478.7 - bone 730.1 - liver (acute) (diffuse) (massive) acute 730.0 (subacute) 570 aseptic or avascular 733.4 -- complicating pregnancy 646.7 ethmoid 478.1 --- fetus or newborn 760.8 jaw 526.4 -- puerperal, postpartum 674.8 tuberculous - see Tuberculosis, bone - lung 513.0 - brain (softening) (see also Softening, - lymphatic gland 683 brain) 437.8 - mammary gland 611.3 - breast (aseptic) (fat) (segmental) 611.3 - mastoid (chronic) 383.1 - bronchi 519.1 - mesentery 557.0 - central nervous system NEC (see also -- fat 567.8 Softening, brain) 437.8 mitral valve - see Insufficiency, mitral - cerebellar (see also Softening, brain) myocardium, myocardial - see Infarct, 437.8 myocardium - cerebral (softening) (see also Softening, nose 478.1 brain) 437.8 - oesophagus 530.8 - cornea (see also Keratitis) 371.4 - omentum 557.0 - cystic medial (aorta) 441.0 -- fat 567.8 - dental 521.0 orbit, orbital 376.1 - esophagus 530.8 - ossicles, ear 385.2 338 INDEX Necrosis - continued Necrosis - continued ovary (see also Salpingo-oophoritis) - subcutaneous fat, fetus or newborn 778.1 614.2 - subendocardial - see Infarct, myocardium pancreas (aseptic) (duct) (fat) 577.8 suprarenal (capsule) (gland) 255.8 -- acute 577.0 - testis 608.8 -- infective 577.0 - thymus (gland) 254.8 - peritoneum 557.0 tonsil 474.8 -- fat 567.8 - tooth, teeth 521.0 - pharynx 462 - trachea 519.1 - phosphorus 983.9 - tuberculous NEe - see Tuberculosis - pituitary (gland) (postpartum) (sheehan) - tubular (acute) (anoxic) (toxic) 584.5 253.2 -- specified due to a procedure 997.5 - placenta (see also Placenta, abnormal) - umbilical cord, affecting fetus or newborn 656.7 762.6 pneumonia 513.0 - vagina 623.8 pulmonary 513.0 - vertebra 730.1 pulp (dental) 522.1 -- acute 730.0 pylorus 537.8 -- tuberculous 015.0 t 730.4* - radiation - see Necrosis, by site - X-ray - see Necrosis, by site - radium - see Necrosis, by site Necrospermia 606 - renal - see Necrosis, kidney Negativism 301.7 - sclera 379.1 Neglect (newborn) 995.5 scrotum 608.8 - after or at birth 995.5 - skin or subcutaneous tissue NEe 785.4 Neisserian infection NEe - see Gonococcus - spine, spinal (column) 730.1 Nematodiasis NEe 127.9 -- acute 730.0 - ancylostoma (see also Ancylostomiasis) -- cord 336.1 126.9 - spleen 289.5 Neonatal - see also condition - stomach 537.8 - tooth, teeth 520.6 - stomatitis 528.1 Neonatorum - see condition Malignant Benign In-situ Un- Un- certain specified be- nature haviour Neoplasm, neoplastic ...................... 199.1 229.9 234.9 238.9 239.9 Notes 1. The list below gives the code numbers for neoplasms by anatomical site. For each site there are five possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behaviour or of unspecified nature. The description of the neoplasm will often indicate which of the five columns is appropriate, e.g. malignant melanoma of skin, benign fibroadenoma of breast, carcinoma in situ of cervix uteri. Where such descriptors are not present, the remainder of the Index should be consulted, where guidance is given to the appropriate column for each morphological (histological) variety listed, e.g. Mesonephroma - see Neoplasm, malignant; Embryoma - see also Neo­ plasm, uncertain behaviour; Disease, Bowen's - see Neoplasm, skin, in situ. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present, e.g. malignant adenoma of colon is coded to 153.9 and not to 211.3 as the adjective "malig­ nant" overrides the Index entry "Adenoma - see also Neoplasm, benign". 2. The first of the five columns gives the code numbers for malignant neoplasms pre­ sumed or stated to be primary. For the code numbers of malignant neoplasms presumed or stated to be secondary, see "Secondary neoplasm". DISEASES AND NATURE OF INJURY 339 3. Sites marked with the sign *' (e.g. face NEC *') should be classified to malignant neoplasm of skin of these sites if the variety of neoplasm is a squamous cell carcinoma or an epidermoid carcinoma and to benign neoplasm of skin of these sites if the variety of neo­ plasm is a papilloma (any type). 4. Carcinomas and adenocarcinomas, of any type other than intraosseous or odontogenic, of sites marked with the sign 0 (e.g. ischium 0) should be considered as constituting meta­ static spread from an unspecified primary site and coded to 198.5 for morbidity coding and to 199.1 for underlying cause of death coding. Malignant Benign In-situ Un- Un- certain specified be- nature haviour Neoplasm - continued - abdomen, abdominal ................... 195.2 229.8 234.8 238.8 239.8 -- cavity ............................... 195.2 229.8 234.8 238.8 239.8 -- organ ............................... 195.2 229.8 238.8 239.8 -- viscera .............................. 195.2 229.8 238.8 239.8 -- wall ................................ 173.5 216.5 232.5 238.2 239.2 - abdominopelvic ........................ 195.8 229.8 238.8 239.8 - accessory sinus - see Neoplasm, sinus - acromion (process) 0 ................... 170.4 213.4 238.0 239.2 - adenoid (tissue) ........................ 147.1 210.7 230.0 235.1 239.0 - adipose tissue - see Neoplasm, connective tissue - adnexa (uterine) ....................... 183.9 221.8 233.3 236.3 239.5 - adrenal (cortex) (gland) (medulla) ........ 194.0 227.0 234.8 237.2 239.7 - ala nasi (external) ...................... 173.3 216.3 232.3 238.2 239.2 - alimentary canal or tract NEC ........... 159.9 211.9 230.9 235.5 239.0 - alveolar -- mucosa ............................. 143.9 210.4 230.0 235.1 239.0 --- lower ............................. 143.1 210.4 230.0 235.1 239.0 --- upper ............................ 143.0 210.4 230.0 235.1 239.0 -- ridge or process 0 .................... 170.1 213.1 238.0 239.2 --- carcinoma ........................ 143.9 ---- lower .......................... 143.1 ---- upper .......................... 143.0 --- lower 0 ........................... 170.1 213.1 238.0 239.2 --- mucosa ..........................
Load more

Recommended publications
  • The Primary Care Pediatrician and the Care of Children with Cleft Lip And/Or Cleft Palate Charlotte W
    CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care The Primary Care Pediatrician Charlotte W. Lewis, MD, MPH, FAAP, a Lisa S. Jacob, DDS, MS, b Christoph U. andLehmann, MD, the FAAP, FACMI, Care c SECTION ON ORALof HEALTH Children With Cleft Lip and/or Cleft Palate Orofacial clefts, specifically cleft lip and/or cleft palate (CL/P), are among the abstract most common congenital anomalies. CL/P vary in their location and severity and comprise 3 overarching groups: cleft lip (CL), cleft lip with cleft palate (CLP), and cleft palate alone (CP). CL/P may be associated with one of many syndromes that could further complicate a child’s needs. Care of patients aDivision of General Pediatrics and Hospital Medicine, Department of with CL/P spans prenatal diagnosis into adulthood. The appropriate timing Pediatrics, University of Washington School of Medicine and Seattle Children’s Hospital, Seattle, Washington; bGeorgetown Pediatric and order of specific cleft-related care are important factors for optimizing Dentistry and Orthodontics, Georgetown, Texas; and Departments of cBiomedical Informatics and Pediatrics, Vanderbilt University Medical outcomes; however, care should be individualized to meet the specific needs Center, Nashville, Tennessee of each patient and family. Children with CL/P should receive their specialty All three authors participated extensively in developing, researching, cleft-related care from a multidisciplinary cleft or craniofacial team with and writing the manuscript and revising it based on reviewers’ comments; Dr Lehmann made additional revisions after review by the sufficient patient and surgical volume to promote successful outcomes. board of directors. The primary care pediatrician at the child’s medical home has an essential This document is copyrighted and is property of the American role in making a timely diagnosis and referral; providing ongoing health Academy of Pediatrics and its Board of Directors.
    [Show full text]
  • S18. Experimental Studies in Cerebrovascular Disease : Echoencephalographic, Electroencephalographic and Histologic Observations
    S17. Experimental Study on intracerebral Hemorrhage Mitsuo TsURU, Kenzoh YADA and Minoru TSUNODA Dept. of Neurosurgery, Hokkaido University School of Medicine Using a physiological pressure transducer, prolonged supratentorial intra- cranial pressure was recorded in cats with experimentally produced intracerebral hematoms, together with recordings of electroencephalogram, arterial and venous pressure, pulse rate, respiration rate, and electrocardiogram. Except for these which die right after the introduction of intracerebral hematoma due to respiratory arrest, the intracranial pressure soon starts to de- cline and continues to decline until it reaches close to normal range. In this stage, although resting intracranial pressure is fairly close to normal, it can extremely easily be elevated by various factors such as minor change of respira- tion, straining etc. We offer to call this appearing normal, but very unstable state of intracranial condition as "latent intracranial hypertension". This im- portant finding gives us warning not to give unnecessary manipulations to the patients with intracranial hematomas even in case they do not seem to have extremely high intracranial pressure. S18. Experimental Studies in Cerebrovascular Disease : Echoencephalographic, Electroencephalographic and Histologic Observations Hajime NAGAI,Kazumi SAKURAI,Masayuki HAYASHI,Kazuhiro FURUSE, Kazuhiko OKAMURA,A. SHINTANI,and T. KOBAYASHI 2nd Dept. of Surgery,School of Medicine,Nagoya University Recent advances in neurosurgery for hypertensive intracerebral hemorrhage have made possible to improve patients suffering from cerebrovascular disease. It is difficult problem, however, to differentiate cerebral hemorrhage from cerebral softening in practice. The purpose of the present paper is to estimate differentiation in both diseases, using echoencephalography and electroencephalography in dogs with experimental- ly produced intracerebral hematoma and cerebral infarction.
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions 001
    SoonerStart Automatic Qualifying Syndromes and Conditions 001 Abetalipoproteinemia 272.5 002 Acanthocytosis (see Abetalipoproteinemia) 272.5 003 Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) 760.79 004 Acidemia, 2-Oxoglutaric 276.2 005 Acidemia, Glutaric I 277.8 006 Acidemia, Isovaleric 277.8 007 Acidemia, Methylmalonic 277.8 008 Acidemia, Propionic 277.8 009 Aciduria, 3-Methylglutaconic Type II 277.8 010 Aciduria, Argininosuccinic 270.6 011 Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) 759.89 012 Acrocephalopolysyndactyly Type II 759.89 013 Acrocephalosyndactyly Type I 755.55 014 Acrodysostosis 759.89 015 Acrofacial Dysostosis, Nager Type 756.0 016 Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) 759.89 017 Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) 759.89 018 Aglossia Congenita (see Hypoglossia-Hypodactylia) 759.89 019 Albinism, Ocular (includes Autosomal Recessive Type) 759.89 020 Albinism, Oculocutaneous, Brown Type (Type IV) 759.89 021 Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) 759.89 022 Albinism, Oculocutaneous, Tyrosinase Positive (Type II) 759.89 023 Albinism, Oculocutaneous, Yellow Mutant (Type IB) 759.89 024 Albinism-Black Locks-Deafness 759.89 025 Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) 759.89 026 Alexander Disease 759.89 027 Alopecia - Mental Retardation 759.89 028 Alpers Disease 759.89 029 Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) 271.0 030 Alpha-L-Fucosidase Deficiency (see Fucosidosis)
    [Show full text]
  • The Role of Intravenous Urography with Erect Film and Retrograde
    Central Journal of Urology and Research Bringing Excellence in Open Access Research Article *Corresponding author Ahmed N. Ghanem, Department of Urology, Consultant Urologist Surgeon, No1 President Mubarak The Role of Intravenous Street, Mansoura 35511, Egypt, Tel: 001020883243; Email: Submitted: 05 November 2018 Urography with Erect Film and Accepted: 22 November 2018 Published: 26 November 2018 Retrograde Pyelography in ISSN: 2379-951X Copyright © 2018 Ghanem et al. Revealing Patho-Etiology of OPEN ACCESS Keywords the Loin Pain and Haematuria • Intravenous urography • Retrograde pyelography • Loin pain haematuria syndrome Syndrome by Discovering • Nephroptosis its Overlooked Link with Symptomatic Nephroptosis Khalid A Ghanem1, Salma A. Ghanem2, Nisha Pindoria3, and Ahmed N. Ghanem1* 1Department of Urology, Mansoura University Hospital, Egypt 2Department of Urology, Barts & The Royal London NHS Trust Royal London Hospital, Egypt 3Department of Urology, North Middlesex University Hospital, Egypt Abstract Introduction and objectives: To report the role of intravenous urography with erect film (IVU-E) and retrograde pyelography (RGP) in resolving the puzzle of Loin Pain and Haematuria Syndrome (LPHS) by revealing its patho-etiological overlooked link with Symptomatic Nephroptosis (SN). We demonstrate that renal pedicle stretch causes neuro-ischaemia as evidenced by the new IVU 7 sign and the damaged renal medullary papilla shown on RGP. Materials and methods: Images are reported from a series of 190 SN patients. Repeated standard imaging was invariably normal, when supine. However, 190 patients demonstrated SN of > 1.5 vertebrae on repeating IVU-E. Of whom 36 (18.9%) patients developed recurrent episodes of painful hematuria for which no organic pathology was detected on all standard imaging, when supine- thus fitting the definition of LPHS.
    [Show full text]
  • Lameness in Fattening Pigs – Mycoplasma Hyosynoviae, Osteochondropathy and Reduced Dietary Phosphorus Level As Three Infuencing Factors: a Case Report
    Lameness in fattening pigs – Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three inuencing factors: A case report Birte Wegner Veterinary Practice Duemmerland Jörg Tenhündfeld Vetland Dr. Tenhündfeld & Kollegen Johanna Vogels Stiftung Tierarztliche Hochschule Hannover Marius Beumer Stiftung Tierarztliche Hochschule Hannover Josef Kamphues Stiftung Tierarztliche Hochschule Hannover Florian Hansmann Stiftung Tierarztliche Hochschule Hannover Hanna Rieger Stiftung Tierarztliche Hochschule Hannover Elisabeth grosse Beilage Stiftung Tierarztliche Hochschule Hannover Isabel Hennig-Pauka ( [email protected] ) University of Veterinary Medicine Hannover https://orcid.org/0000-0003-3994-5979 Case report Keywords: Locomotor disorder, mineral supply, Mycoplasma hyosynoviae, nutrition, swine Posted Date: September 25th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-35962/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/28 Version of Record: A version of this preprint was published on December 15th, 2020. See the published version at https://doi.org/10.1186/s40813-020-00184-w. Page 2/28 Abstract Background: Multiple diagnostic procedures, their results and interpretation in a case with severe lameness in fattening pigs are described. It is shown that selected diagnostic steps lead to identication of various risk factors for disease development in the affected herd. One focus of this case report is the prioritization of diagnostic steps to verify the impact of the different conditions, which nally led to the clinical disorder. Disease is the consequence of previously acting factors, and the involved diagnostic institute is the last stage in the timeline. Some diagnostic ndings might therefore no longer be signicant.
    [Show full text]
  • A Molecular and Genetic Analysis of Otosclerosis
    A molecular and genetic analysis of otosclerosis Joanna Lauren Ziff Submitted for the degree of PhD University College London January 2014 1 Declaration I, Joanna Ziff, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Where work has been conducted by other members of our laboratory, this has been indicated by an appropriate reference. 2 Abstract Otosclerosis is a common form of conductive hearing loss. It is characterised by abnormal bone remodelling within the otic capsule, leading to formation of sclerotic lesions of the temporal bone. Encroachment of these lesions on to the footplate of the stapes in the middle ear leads to stapes fixation and subsequent conductive hearing loss. The hereditary nature of otosclerosis has long been recognised due to its recurrence within families, but its genetic aetiology is yet to be characterised. Although many familial linkage studies and candidate gene association studies to investigate the genetic nature of otosclerosis have been performed in recent years, progress in identifying disease causing genes has been slow. This is largely due to the highly heterogeneous nature of this condition. The research presented in this thesis examines the molecular and genetic basis of otosclerosis using two next generation sequencing technologies; RNA-sequencing and Whole Exome Sequencing. RNA–sequencing has provided human stapes transcriptomes for healthy and diseased stapes, and in combination with pathway analysis has helped identify genes and molecular processes dysregulated in otosclerotic tissue. Whole Exome Sequencing has been employed to investigate rare variants that segregate with otosclerosis in affected families, and has been followed by a variant filtering strategy, which has prioritised genes found to be dysregulated during RNA-sequencing.
    [Show full text]
  • C.O.E. Continuing Education Curriculum Coordinator
    CONTINUING EDUCATION All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O. E. Continuing Education. The course provided was prepared by C.O.E. Continuing Education Curriculum Coordinator. It is not meant to provide medical, legal or C.O.E. professional services advice. If necessary, it is recommended that you consult a medical, legal or professional services expert licensed in your state. Page 1 of 199 Click Here To Take Test Now (Complete the Reading Material first then click on the Take Test Now Button to start the test. Test is at the bottom of this page) 5 hr. Nail Structure and Growth & TCSG Health and Safety Outline Why Study Nail Structure and Growth? • The Natural Nail • Nail Anatomy • Nail Growth • Know Your Nails Objectives After completing this section, you should be able to: C.O.E.• Describe CONTINUING the structure and composition of nails. EDUCATION • Discuss how nails grow. • Identify diseases and disorders of the nail All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O. E. Continuing Education. The course provided was prepared by C.O.E. Continuing Education Curriculum Coordinator. It is not meant to provide medical, legal or professional services advice. If necessary, it is recommended that you consult a medical, legal or professional services expert licensed in your state. 1 CONTINUING EDUCATION All Rights Reserved. Materials may not be copied, edited, reproduced, distributed, imitated in any way without written permission from C.O.
    [Show full text]
  • Frequency and Criticality of Diagnoses in Family Medicine Practices: from the National Ambulatory Medical Care Survey (NAMCS)
    J Am Board Fam Med: first published as 10.3122/jabfm.2018.01.170209 on 12 January 2018. Downloaded from ORIGINAL RESEARCH Frequency and Criticality of Diagnoses in Family Medicine Practices: From the National Ambulatory Medical Care Survey (NAMCS) Michael R. Peabody, PhD, Thomas R. O’Neill, PhD, Keith L. Stelter, MD, MMM, and James C. Puffer, MD Background: Family medicine is a specialty of breadth, providing comprehensive health care for the individual and the family that integrates the broad scope of clinical, social, and behavioral sciences. As such, the scope of practice (SOP) for family medicine is extensive; however, over time many family phy- sicians narrow their SOP. We sought to provide a nationally representative description of the most com- mon and the most critical diagnoses that family physicians see in their practice. Methods: Data were extracted from the 2012 National Ambulatory Medical Care Survey (NAMCS) to select all ICD-9 codes reported by family physicians. A panel of family physicians then reviewed 1893 ICD-9 codes to place each code into an American Board of Family Medicine Family Medicine Certifica- tion Examination test plan specifications (TPS) category and provide a rating for an Index of Harm (IoH). Results: An analysis of all 1893 ICD-9 codes seen by family physicians in the 2012 NAMCS found that 198 ICD-9 codes could not be assigned a TPS category, leaving 1695 ICD-9 codes in the dataset. Top 10 lists of ICD-9 codes by TPS category were created for both frequency and IoH. Conclusions: This study provides a nationally representative description of the most common diag- copyright.
    [Show full text]
  • MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002
    MICHIGAN BIRTH DEFECTS REGISTRY Cytogenetics Laboratory Reporting Instructions 2002 Michigan Department of Community Health Community Public Health Agency and Center for Health Statistics 3423 N. Martin Luther King Jr. Blvd. P. O. Box 30691 Lansing, Michigan 48909 Michigan Department of Community Health James K. Haveman, Jr., Director B-274a (March, 2002) Authority: P.A. 236 of 1988 BIRTH DEFECTS REGISTRY MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BIRTH DEFECTS REGISTRY STAFF The Michigan Birth Defects Registry staff prepared this manual to provide the information needed to submit reports. The manual contains copies of the legislation mandating the Registry, the Rules for reporting birth defects, information about reportable and non reportable birth defects, and methods of reporting. Changes in the manual will be sent to each hospital contact to assist in complete and accurate reporting. We are interested in your comments about the manual and any suggestions about information you would like to receive. The Michigan Birth Defects Registry is located in the Office of the State Registrar and Division of Health Statistics. Registry staff can be reached at the following address: Michigan Birth Defects Registry 3423 N. Martin Luther King Jr. Blvd. P.O. Box 30691 Lansing MI 48909 Telephone number (517) 335-8678 FAX (517) 335-9513 FOR ASSISTANCE WITH SPECIFIC QUESTIONS PLEASE CONTACT Glenn E. Copeland (517) 335-8677 Cytogenetics Laboratory Reporting Instructions I. INTRODUCTION This manual provides detailed instructions on the proper reporting of diagnosed birth defects by cytogenetics laboratories. A report is required from cytogenetics laboratories whenever a reportable condition is diagnosed for patients under the age of two years.
    [Show full text]
  • IQI 17 Acute Stroke Mortality Rate
    AHRQ Quality Indicators™ (AHRQ QI™) ICD-10-CM/PCS Specification v2021 Inpatient Quality Indicator 17 (IQI 17) Acute Stroke Mortality Rate July 2021 Hospital-Level Indicator Type of Score: Rate Prepared by: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services www.qualityindicators.ahrq.gov DESCRIPTION In-hospital deaths per 1,000 hospital discharges with a principal diagnosis of acute stroke for patients ages 18 years and older. Includes metrics for discharges grouped by type of stroke. Excludes transfers to another hospital, cases admitted from a hospice facility, and obstetric discharges. [NOTE: The software provides the rate per hospital discharge. However, common practice reports the measure as per 1,000 discharges. The user must multiply the rate obtained from the software by 1,000 to report in-hospital deaths per 1,000 hospital discharges.] Stratification of Indicator The indicator is stratified into three groups by the type of stroke: Cases are assigned to strata according to a hierarchy based on risk of mortality, with cases being assigned to the stratum with the highest mortality for which the case qualifies. In the case of Stroke Mortality the current hierarchy is as follows: Strata hierarchy (listed from highest mortality to lowest mortality): 1) Intracerebral hemorrhage 2) Subarachnoid hemorrhage 3) Ischemic stroke Strata are mutually exclusive. If a discharge qualifies for more than one stratum, it will be assigned to the stratum with the highest risk of mortality (Intracerebral hemorrhage, Subarachnoid hemorrhage, Ischemic stroke). July 2021 1 of 7 AHRQ QI™ ICD-10-CM/PCS Specification v2021 IQI 17 Acute Stroke Mortality Rate www.qualityindicators.ahrq.gov NUMERATOR Overall Number of deaths (DISP=20) among cases meeting the inclusion and exclusion rules for the denominator.
    [Show full text]
  • Concomitant Manifestation of Pili Annulati and Alopecia Areata: Coincidental Rather Than True Association
    Acta Derm Venereol 2011; 91: 459–462 CLINICAL REPORT Concomitant Manifestation of Pili Annulati and Alopecia Areata: Coincidental Rather than True Association Kathrin A. GIEHL1, Matthias SCHMUTH2, Antonella TOSTI3, David A. De BERKER4, Alexander CRISPIN5, Hans WOLFF1 and Jorge FRANK6,7 Department of Dermatology, 1Ludwig-Maximilian University, Munich, Germany, 2Medical University Innsbruck, Austria, 3University of Bologna, Italy, 4University of Bristol, UK, 5Department of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilian University, Munich, Germany, 6Depart- ment of Dermatology, and 7GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center (MUMC), The Netherlands The autosomal dominantly inherited hair disorder pili with these cavities, most patients with PA do not report annulati is characterized by alternating light and dark increased hair fragility (5, 6). bands of the hair shaft. Concomitant manifestation of A locus for PA has been shown on chromosome pili annulati with alopecia areata has been reported 12p24.32–24.33 (7, 8). A previous study of hair follicle previously on several occasions. However, no systematic morphology indicates that the disease may arise from evaluation of patients manifesting both diseases has been a defect that putatively affects a regulatory element performed. We studied the simultaneous or sequential involved in the assembly of structural proteins within occurrence of pili annulati and alopecia areata in indi- the extracellular matrix (9). viduals diagnosed in different European academic der- In contrast to PA, alopecia areata (AA) is a polyge- matology units. We included 162 Caucasian individuals netic, immune-mediated disorder of the hair follicle from 14 extended families, comprising 76 affected and that has an unpredictable, and sometimes self-limiting, 86 unaffected family members.
    [Show full text]
  • Revisiting Hair Follicle Embryology, Anatomy and the Follicular Cycle
    etology sm & o C T r f i o c h l o a l n o r Silva et al., J Cosmo Trichol 2019, 5:1 g u y o J Journal of Cosmetology & Trichology DOI: 10.4172/2471-9323.1000141 ISSN: 2471-9323 Review Article Open Access Revisiting Hair Follicle Embryology, Anatomy and the Follicular Cycle Laura Maria Andrade Silva1*, Ricardo Hsieh2, Silvia Vanessa Lourenço3, Bruno de Oliveira Rocha1, Ricardo Romiti4, Neusa Yuriko Sakai Valente4,5, Alessandra Anzai4 and Juliana Dumet Fernandes1 1Department of Dermatology, Magalhães Neto Outpatient Clinic, Professor Edgar Santos School Hospital Complex, The Federal University of Bahia (C-HUPES/UFBa), Salvador/BA-Brazil 2Institute of Tropical Medicine of São Paulo, The University of São Paulo (IMT/USP), São Paulo/SP-Brazil 3Department of Stomatology, School of Dentistry, The University of São Paulo (FO/USP), São Paulo/SP-Brazil 4Department of Dermatology, University of São Paulo Medical School, The University of São Paulo (FMUSP), São Paulo/SP-Brazil 5Department of Dermatology, Hospital of the Public Server of the State of São Paulo (IAMSPE), São Paulo/SP-Brazil *Corresponding author: Laura Maria Andrade Silva, Department of Dermatology, Magalhães Neto Outpatient Clinic, Professor Edgar Santos School Hospital Complex, The Federal University of Bahia (C-HUPES/UFBa) Salvador/BA-Brazil, Tel: +55(71)3283-8380; +55(71)99981-7759; E-mail: [email protected] Received date: January 17, 2019; Accepted date: March 07, 2019; Published date: March 12, 2019 Copyright: © 2019 Silva LMA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]